TG Therapeutics Inc (NASDAQ: TGTX) on Friday, soared 9.24% from the previous trading day, before settling in for the closing price of $35.19. Within the past 52 weeks, TGTX’s price has moved between $12.93 and $37.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 2514.62%. The company achieved an average annual earnings per share of 560.00%. With a float of $141.36 million, this company’s outstanding shares have now reached $155.84 million.
Let’s determine the extent of company efficiency that accounts for 338 employees. In terms of profitability, gross margin is 88.26%, operating margin of 12.74%, and the pretax margin is 7.78%.
TG Therapeutics Inc (TGTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of TG Therapeutics Inc is 10.00%, while institutional ownership is 62.33%. The most recent insider transaction that took place on Jan 03 ’25, was worth 343,443. In this transaction CFO of this company sold 11,337 shares at a rate of $30.29, taking the stock ownership to the 670,632 shares. Before that another transaction happened on Jan 06 ’25, when Company’s CFO sold 10,021 for $28.53, making the entire transaction worth $285,939. This insider now owns 660,611 shares in total.
TG Therapeutics Inc (TGTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 560.00% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
TG Therapeutics Inc (TGTX) is currently performing well based on its current performance indicators. A quick ratio of 5.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.14, a number that is poised to hit 0.16 in the next quarter and is forecasted to reach 1.93 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
Looking closely at TG Therapeutics Inc (NASDAQ: TGTX), its last 5-days average volume was 5.7 million, which is a jump from its year-to-date volume of 2.56 million. As of the previous 9 days, the stock’s Stochastic %D was 84.13%. Additionally, its Average True Range was 2.10.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 99.17%, which indicates a significant increase from 98.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.55% in the past 14 days, which was higher than the 67.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.30, while its 200-day Moving Average is $25.40. However, in the short run, TG Therapeutics Inc’s stock first resistance to watch stands at $39.90. Second resistance stands at $41.36. The third major resistance level sits at $44.14. If the price goes on to break the first support level at $35.66, it is likely to go to the next support level at $32.88. Now, if the price goes above the second support level, the third support stands at $31.42.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
Market capitalization of the company is 6.04 billion based on 157,071K outstanding shares. Right now, sales total 233,660 K and income totals 12,670 K. The company made 83,880 K in profit during its latest quarter, and 3,880 K in sales during its previous quarter.
